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 38 
ABSTRACT 39 
Background 40 
We aimed to compare differences in risk and timing of recurrent ischemic events among patients with 41 
stable ischemic heart disease (SIHD), non–ST-segment elevation acute coronary syndrome (NSTE-42 
ACS), and ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary 43 
intervention (PCI). 44 
 45 
Methods 46 
We performed an individual data pooled analysis of 5 randomized controlled all-comer trials including 47 
a total of 8,859 patients and investigated the risk and timing of recurrent ischemic events among 48 
patients with SIHD (n = 3,543), NSTE-ACS (n = 3,364), and STEMI (n = 1,952) throughout 2 years of 49 
follow-up. 50 
 51 
Results  52 
At 2 years, all-cause mortality was higher among patients with STEMI (6.4%) and NSTE-ACS (6.1%) 53 
compared with those with SIHD (4.2%) (STEMI vs SIHD: hazard ratio [HR] 1.40, 95% CI 1.09-1.78, P = 54 
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.007; NSTE-ACS vs SIHD: 1.40, 95% CI 1.13-1.73, P = .002). In a landmark analysis, the risk of mortality 55 
among patients with STEMI compared with those with SIHD was confined to the first 30 days after PCI 56 
(HR 6.19, 95% CI 3.15-12.16, P < .001) but was similar between 30 days and 2 years (HR 1.00, 95%CI 57 
0.76-1.33, P = .974) (Pinteraction < .001).Conversely, patients with NSTE-ACS had a higher risk ofmortality 58 
compared with thosewith SIHDbothwithin the first 30days (HR 2.19,95%CI 1.08-4.47, P = .031) and 59 
beyond (HR 1.34, 95%CI 1.07-1.67, P = .012) (Pinteraction < .001). A similar pattern in the differential 60 
timing of events was observed for cardiac death. Beyond 30 days, the risk of myocardial infarction was 61 
comparable in patients with STEMI and SIHD, whereas the risk in patients with NSTE-ACS was 62 
increased (HR 1.65, 95% CI 1.23-2.21, P = .001). 63 
 64 
Conclusion 65 
Whereas patientswithNSTE-ACS are at increased risk for death at any time after PCI, the mortality of 66 
STEMI patients is higher during the first 30 days after PCI but not thereafter compared with patients 67 
with SIHD. (Am Heart J 2016;175:56-65.). 68 
  69 
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METHODS 70 
Study population 71 
We pooled individual patient data from 5 randomized controlled trials conducted between 2003 and 72 
2014 including a total of 8,859 patients: the sirolimus-eluting and paclitaxel-eluting stent for coronary 73 
revascularization (SIRTAX) trial (n = 1,012),8 the biolimus-eluting stent with biodegradable polymer 74 
versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS) trial (n 75 
= 1,707),9 the comparison of zotarolimus-eluting and everolimus-eluting coronary stents (RESOLUTE 76 
All Comers) trial (n = 2,018),10 the prolonging dual antiplatelet treatment after grading stent-induced 77 
intimal hyperplasia study (PRODIGY) (n = 2,003),11 and the comparison of ultrathin strut biodegradable 78 
polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents (BIOSCIENCE) trial 79 
(n = 2,119).12 Broad inclusion criteria were applied in all included trials consistent with an all-comers 80 
study design. Details of the individual trials have been published elsewhere.8-12 The trials complied 81 
with the Declaration of Helsinki and were approved by the ethics committee of each study site. All 82 
patients provided written informed consent for participation in the study. No extramural funding was 83 
used to support this work. The authors are solely responsible for the design and conduct of this study, 84 
all study analyses, the drafting and editing of the paper, and its final contents. 85 
 86 
Procedures 87 
Balloon angioplasty and stent implantation were performed according to standard techniques and 88 
guidelines current at the time of the study. Periprocedural anticoagulation was accomplished with 89 
unfractionated heparin or bivalirudin; the use of glycoprotein IIb/IIIa inhibitors was left to the 90 
discretion of the operator. Dual antiplatelet treatment consisted of acetylsalicylic acid of at least 75 91 
mg daily and a P2Y12-inhibitor in all trials, and was prescribed for at least 12 months in the SIRTAX, 92 
the LEADERS, and the BIOSCIENCE trials8,9,12 and for at least 6 months in the RESOLUTE All Comers 93 
trial.10 In the PRODIGY trial, patients were randomized at 30 days in a balanced fashion to either 6 or 94 
24 months of dual antiplatelet treatment.11 Among patients treated with bare metal stents for SIHD, 95 
clopidogrel discontinuation was allowed at any time beyond 30 days. 96 
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Definitions 97 
The primary end point of the present analysis was all-cause mortality. Secondary end points were 98 
cardiac death, MI, definite stent thrombosis, and definite and probable stent thrombosis according to 99 
the Academic Research Consortium criteria.13 End point definitions were comparable across the 4 100 
trials included in the present analysis and consistent with the definitions proposed by the Academic 101 
Research Consortium13 in the majority of trials.  102 
Cardiac death was defined as death from cardiac causes or any death from unknown causes in SIRTAX, 103 
LEADERS, and BIOSCIENCE,8,9,12 and as any death unless an undisputed noncardiac cause was present 104 
in the RESOLUTE All Comers trial.10 Myocardial infarction was defined in SIRTAX and LEADERS as the 105 
presence of new Q waves in at least 2 contiguous leads and an elevated creatine kinase–MB fraction 106 
or—in the absence of significant Q waves—as an increase in the creatine kinase level to more than 107 
twice the upper limit of the reference range with an elevated level of creatine kinase–MB or 108 
troponin.8,9 In the RESOLUTE All Comers and the BIOSCIENCE trials, myocardial infarction was defined 109 
according to an “extended historical” definition consistent with the one used in SIRTAX and LEADERS.10 110 
In PRODIGY, the definition of myocardial infarction was based on the detection of increase and/or 111 
decrease in creatine kinase–MB or troponin with at least 1 value above the upper limit of normal 112 
together with evidence of myocardial ischemia with at least 1 of the following: symptoms of ischemia, 113 
electrocardiographic changes indicative of new ischemia (new ST-T changes or new left bundle-branch 114 
block), and development of pathological Q waves.11 115 
 116 
Statistical analysis 117 
The baseline and procedural characteristics are presented as means ± SD in case of continuous 118 
variables and as frequencies and percentages in case of categorical variables. The P values for 119 
differences across groups are from χ2 tests, linear regression (baseline characteristics), or Poisson 120 
regression (procedural characteristics). The clinical outcomes at 30 days, 1 year, and 2 years are 121 
presented as counts using Kaplan-Meier incidence rate and illustrated as cumulative incidence both 122 
with and without landmark analysis at 30 days. We present both crude and adjusted hazard ratios 123 
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(HRs) for the clinical outcomes at 30 days, 1 year, and 2 years. We adjusted for age, gender, body mass 124 
index, diabetes, hypertension, hypercholesterolemia, previous MI, glomerular filtration rate, left 125 
ventricular ejection fraction, and type of stent. The difference across groups was estimated from Cox 126 
regressions. We refrained from stratifying the analyses according to stent type. All hypotheses were 127 
2-sided, and a P value < .05 was deemed statistically significant. All tests of differences across groups 128 
take into account the cluster effect of the trials. The statistical analyses were performed with Stata 129 
(version 13.1). 130 
 131 
RESULTS 132 
Among 8,859 patients enrolled in 5 trials, 3,543 patients (40%) presented with SIHD, 3,364 with NSTE-133 
ACS (38%), and 1,952 with STEMI (22%). Two-year clinical follow-up was complete in 8,673 patients 134 
(98%). Baseline clinical characteristics are summarized in Table I. Patients presenting with SIHD and 135 
NSTE-ACS had a similar cardiovascular risk profile. In contrast, STEMI patients less frequently had 136 
diabetes (14% vs 27%, P < .001), hypertension (53% vs 73%, P < .001), or hypercholesterolemia (44% 137 
vs 73%, P < .001) as compared with patients with SIHD. Along the same line, patients with NSTE-ACS 138 
and SIHD more commonly had a history of previous MI and previous revascularization procedures. 139 
Both patients with STEMI (47% ± 11%) and NSTE-ACS (55% ± 11%) had a lower systolic left ventricular 140 
ejection fraction compared with patients with SIHD (58% ± 11%) (P < .001 andP = .006, respectively). 141 
Procedural characteristics are shown in Table II. Patients with STEMI had fewer lesions as compared 142 
with patients with SIHD (1.4 ± 0.7 vs 1.5 ± 0.8, P < .001); moreover, we observed a trend toward a 143 
lower number of vessels treated per patient among patients with STEMI as compared with patients 144 
with SIHD (1.2 ± 0.5 vs 1.3 ± 0.5, P < .001). 145 
Tables IIIA and IIIB summarize crude and adjusted clinical outcomes at 30 days, 1 year, and 2 years, 146 
respectively. All-cause mortality at 30 days amounted to 2.2% among patients with STEMI, 0.7% 147 
among patients with NSTE-ACS, and 0.3% among patients with SIHD (STEMI vs SIHD adj HR 7.36, 95% 148 
CI 2.83-19.13, P b .001; NSTE-ACS vs SIHD adj HR 2.65, 95% CI 1.050-6.67, P = .038). At 2 years, all-149 
cause mortality among patients with STEMI, NSTE-ACS, and SIHD was 6.4%, 6.1%, and 4.2%, 150 
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respectively (STEMI vs SIHD adj HR 1.54, 95% CI 1.12-2.11, P = .007; NSTE-ACS vs SIHD adj HR 1.37, 151 
95% CI 1.06-1.78, P = .018) (Figure 1, A). In a landmark analysis shown in Figure 1, B and Table IV, the 152 
risk of all-cause mortality was increased among patients with STEMI as compared with those with SIHD 153 
within the first 30 days after PCI (HR 6.19, 95% CI 3.15-12.16, P < .001) but was similar between 31 154 
days and 2 years (HR 1.0, 95% CI 0.76-1.33, P = .974) (P for interaction < .001). In contrast, patients 155 
with NSTE-ACS had a higher risk of all-cause mortality compared with those with SIHD both within the 156 
first 30 days (HR 2.19, 95% CI 1.08-4.47, P = .031) and beyond (HR 1.34, 95% CI 1.07-1.67, P = .012). A 157 
similar pattern in the differential timing of events among patients with STEMI, NSTE-ACS, and SIHD 158 
was observed for cardiac death (Figure 2, A and B; Table IV). 159 
Myocardial infarctions occurred less frequently among patients with STEMI as compared with SIHD 160 
throughout 2 years of follow-up (5.1% vs 7.2%, adj HR 0.58, 95% CI 0.43-0.78, P b .001). The difference 161 
was driven by a lower incidence of MI among patients with STEMI within the first 30 days (HR 0.38, 162 
95% CI 0.28-0.53, P < .001), whereas no difference was documented for the time between 30 days and 163 
2 years (HR 1.00, 95% CI 0.69-1.44, P = .980) (Figure 3, Table IV). There was no significant difference 164 
in the rate of MIs among patients with NSTE-ACS as compared with SIHD overall (9.0% vs 7.2%, adj HR 165 
1.12, 95% CI 0.94-1.32, P = .197). However, there was a higher risk of MI in the period from 31 days to 166 
2 years among patients with NSTE-ACS as compared with SIHD (HR 1.65, 95% CI 1.23-2.21, P = .001) 167 
(Table IV). 168 
Rates of definite stent thrombosis amounted to 2.3%, 1.4%, and 1.3% among patients with STEMI, 169 
NSTE-ACS, and SIHD, respectively (STEMI vs SIHD adj HR 1.92, 95% CI 1.25-2.92, P = .003; NSTE-ACS vs 170 
SIHD adj HR 1.10, 95% CI 0.73-1.67, P = .652). In a landmark analysis with the landmark at 30 days, the 171 
increased risk of stent thrombosis among STEMI patients as compared with patients with SIHD was 172 
confined to the first 30 days (HR 2.54, 95% CI 1.45-4.43, P = .001), whereas the subsequent risk was 173 
comparable (HR 1.27, 95% CI 0.65-2.48, P = .482) (Figure 4, Table IV). There was no difference in the 174 
risk of stent thrombosis between patients with NSTE-ACS or SIHD within 30 days (HR 1.01, 95% CI 0.56-175 
1.84, P = .961) and beyond (HR 1.18, 95% CI 0.66-2.12, P = .577). The findings were consistent in crude 176 
and adjusted analysis, respectively (Table IV). 177 
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DISCUSSION 178 
In the present individual data pooled analysis of 5 randomized controlled all-comer trials, we observed 179 
a differential in timing of ischemic events according to presentation with STEMI, NSTE-ACS, or SIHD. 180 
The principal findings of our analysis can be summarized as follows: (1) Patients with NSTE-ACS and 181 
SIHD had a comparable risk profile at baseline, whereas patients with STEMI had a lower prevalence 182 
of cardiovascular risk factors and less frequently had a history of prior cardiovascular disease. (2) 183 
Patients with STEMI had a lower risk of recurrent MI compared with patients with SIHD throughout 2 184 
years of follow-up. Although the risk of MI among patients with NSTE-ACS and SIHD was comparable 185 
throughout 2 years, we observed an increased risk of MI beyond the periprocedural period among 186 
patients with NSTE-ACS as compared with those with SIHD. (3) The increased risk of 30-day mortality 187 
among patients with STEMI as compared with those with SIHD was no longer apparent beyond 30 188 
days of follow-up. In contrast, patients with NSTE-ACS had an increased risk of death as compared 189 
with those with SIHD which was sustained during the entire time of follow-up. 190 
Patients undergoing PCI for NSTE-ACS or SIHD were found to have a similar prevalence of 191 
cardiovascular risk factors and comparable rates of previous revascularization procedures. In contrast, 192 
patients with STEMI were characterized by a lower rate of cardiovascular risk factors and fewer 193 
previous cardiac revascularization procedures. Moreover, patients with STEMI tended to be younger 194 
compared with patients with SIHD or NSTE-ACS and had fewer coronary lesions. STEMI may often 195 
represent the first manifestation of cardiovascular disease and results from rupture of vulnerable 196 
plaques without underlying significant coronary stenosis. Conversely, NSTE-ACS and SIHD referred for 197 
PCI may indicate advanced stages of disease with a higher number of lesions with hemodynamically 198 
significant stenosis and more gradual clinical manifestation. Absence of previous medical contacts in 199 
patients presenting with STEMI as a first manifestation of coronary artery disease may be associated 200 
with a higher rate of underdiagnosed risk factors and may have increased the risk of acquisition bias. 201 
Patients undergoing PCI for NSTE-ACS were at highest risk to experience a recurrent MI within the 202 
subsequent 2 years, followed by patients with SIHD and STEMI, respectively. Several reasons may 203 
account for this finding. A low rate of recurrent MI may be related to ascertainment bias due to 204 
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differences in definition related to periprocedural MI in the setting of STEMI as compared with SIHD; 205 
whereas the risk of recurrent MI among patients with STEMI was low within the first 30 days after PCI, 206 
a landmark analysis showed no significant difference in rates of MI beyond the periprocedural period. 207 
In addition, the increased risk of recurrent MI may be related to a higher atherosclerotic burden and 208 
therefore more advanced CAD among patient with NSTE-ACS and SIHD as compared with patients 209 
with STEMI. However, an increased risk of MI beyond the periprocedural period among patients with 210 
NSTE-ACS as compared with those with SIHD calls for an additional explanation. Progression of disease 211 
may be related to culprit or nonculprit lesions14. The inflammatory milieu in patients with acute 212 
coronary syndromes has been associated with generalized plaque vulnerability not limited to the 213 
culprit lesion. Healing of ruptured plaques stimulates progression of luminal narrowing and propels 214 
coronary artery disease.15 Indeed, a recent experimental study in mice suggests that acute MI 215 
accelerates atherosclerosis by activating the chronic inflammatory disease process.3 This mechanism 216 
may be responsible for recurrent MIs in nonculprit lesions. Furthermore, intravascular imaging studies 217 
of culprit lesions have suggested a delayed healing response among patients with acute coronary 218 
syndromes as compared with those with SIHD that was attributable to baseline lesion characteristics.16 219 
The latter in turn may increase the risk for repeat MIs related to the culprit vessel.  220 
The risk of definite stent thrombosis was highest among patients presenting with STEMI, largely driven 221 
by more than 2-fold increased risk of stent thrombosis within the first 30 days after PCI in patients 222 
with STEMI as compared with SIHD. This finding is likely explained by the prothrombotic milieu of 223 
acute MI and is consistent with existing literature. 224 
After 2 years of follow-up, patients with STEMI and NSTE-ACS had numerically comparable mortality 225 
rates that were 1.5 times higher than in patients with SIHD. A similar pattern was observed across the 226 
3 groups for cardiac mortality. However, we observed an important differential in timing of all-cause 227 
and cardiac mortality. An increased risk of death within the first 30 days after STEMI was offset 228 
between 30 days and 2 years compared with patients with SIHD. In contrast, patients with NSTE-ACS 229 
experienced an increased risk of death compared with patients with SIHD irrespective of time after 230 
the intervention. Our findings are consistent with previous reports. In an analysis of 4,387 patients in 231 
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the United States, patients with STEMI had a higher adjusted mortality risk during the first 2 months 232 
as compared with patients with NSTE-ACS (adj HR 1.85, 95% CI 1.45-2.38) and a lower risk of mortality 233 
beyond 2 months (adj HR 0.68, 95% CI 0.59-0.83). However, rates of index revascularization were 234 
rather low and amounted to 75% among patients with STEMI and 56% among patients with NSTE-ACS, 235 
respectively.5 Adverse long-term outcome among patients with NSTE-ACS as compared with patients 236 
with STEMI has been associated with a higher prevalence of comorbidities, a greater extent of 237 
coronary artery disease, and lower rates of revascularization.5 More recent data from South Korea 238 
corroborated these findings in >28,000 patients with STEMI or NSTE-ACS. Whereas the rates of major 239 
adverse cardiovascular events and cardiac mortality were higher in patients with STEMI as compared 240 
with patients with NSTE-ACS within the first 30 days (6.9% vs 4.5%, P b .001), reverse event rates were 241 
observed during the time period between 30 days and 2 years (STEMI 8.0% vs NSTE-ACS 9.1%, P = 242 
.007). Risk factors for both early and late cardiac death in patients with STEMI or NSTE-ACS were 243 
reduced left ventricular ejection fraction and clinical sings of congestive heart failure according to Killip 244 
class.6 In another analysis of 13,441 patients in Poland, an adverse long-term prognosis observed in 245 
patients with NSTE-ACS as compared with patients with STEMI was offset after adjustment for 246 
baseline characteristics and treatment strategy.7 In contrast to the above-mentioned reports, all 247 
patients included into the present analysis underwent PCI, hence eliminating the potential confounder 248 
of revascularization. 249 
The present analysis has several limitations. First, only patients undergoing PCI were included in the 250 
present analysis, which introduces a selection bias, particularly among patients with SIHD. Patients 251 
with SIHD undergoing conservative management are not represented in the present analysis. In turn, 252 
revascularization has been identified as a confounder in previous analyses comparing patients with 253 
STEMI and NSTE-ACS only. Second, there were some minor differences in definitions of adverse events 254 
across trials. In particular, the assessment of periprocedural MIs may have been more difficult among 255 
patients with ongoing MI. In contrast, all patients were included into randomized controlled trials with 256 
a high data quality, meticulous follow-up, and independent event adjudication. Third, the combination 257 
of 5 all-comer trials performed during a time span of 10 years may be confounded by differences in 258 
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temporal trends in revascularization therapy and optimal medical treatment. No comprehensive 259 
information on medical management and adherence to secondary prevention after PCI was available. 260 
Prolonged duration of dual antiplatelet treatment beyond 1 year or combination with novel P2Y12 261 
ADP-receptor antagonists might have decreased the number of ischemic events. Fourth, in view of a 262 
noticeable gradient of risk across all ischemic outcomes, the absence of a significant difference 263 
between patients with STEMI or SIHD in our analysis may reflect a lack of power. And finally, clinical 264 
follow-up was limited to 2 years. We do not know to what extent the results can be extrapolated to 265 
long-term clinical follow-up. 266 
 267 
CONCLUSION 268 
The risk and timing of recurrent ischemic events differ importantly between patients with STEMI, 269 
NSTE-ACS, and SIHD after PCI. Whereas patients with NSTE-ACS are at increased risk for death at any 270 
time after PCI, the mortality of STEMI patients is increased during the first 30 days after PCI but not 271 
thereafter compared with patients with SIHD. 272 
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IMPACT ON DAILY PRACTICE  280 
The findings of the present study show a time variable pattern of recurrent events following PCI 281 
according to presentation with SIHD, NSTE-ACS, or STEMI, respectively, which may have important 282 
implications for long-term medical management and secondary prevention. 283 
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TABLES 330 
Table I 331 
Baseline clinical characteristics. Values are means (SD) or number (percentage). GFR, glomerular 332 
filtration rate; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction. 333 
 334 
 335 
Table II  336 
Procedural characteristics. Depicted are means ± SD with P values from Poisson regression or counts 337 
(percentage) with P values from χ2 tests. All tests take into account the clustering of patients in trials. 338 
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Table IIIA: 340 
Clinical outcomes at 30 days, 1 year, and 2 years (crude analysis). Depicted are counts (Kaplan-Meier 341 
incidence rates %). Hazard ratios (95% CI) and P values are from Cox regressions taking into account 342 
the trial effect. 343 
 344 
 345 
Table IIIB: 346 
Clinical outcomes at 30 days, 1 year, and 2 years (adjusted analysis). Depicted are counts (Kaplan-347 
Meier incidence rates %). Hazard ratios (95% CI) and P values are from Cox regressions taking into 348 
account the trial effect. Adjustment baseline variables are age, gender, body mass index, diabetes, 349 
hypertension, hypercholesterolemia, previous MI, GFR, LVEF, and type of stent. 350 
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Table IV: 352 
Landmark analysis for clinical Outcomes. 353 
 354 
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FIGURES 356 
Figure 1A: All-cause mortality. The solid black line indicates patients with STEMI, the dotted blue line 357 
patients with NSTE-ACS, and the dotted green line patients with SIHD.  358 
Figure 1B: Landmark analysis of all-cause mortality with the landmark set at 30 days. The solid black 359 
line indicates patients with STEMI, the dotted blue line patients with NSTE-ACS, and the dotted green 360 
line patients with SIHD. 361 
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Figure 2A: Cardiac mortality. The solid black line indicates patients with STEMI, the dotted blue line 363 
patients with NSTE-ACS, and the dotted green line patients with SIHD. 364 
Figure 2B: Landmark analysis of cardiac mortality with the landmark set at 30 days. The solid black line 365 
indicates patients with STEMI, the dotted blue line patients with NSTE-ACS, and the dotted green line 366 
patients with SIHD. 367 
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Figure 3:  369 
Landmark analysis of MI with the landmark set at 30 days. The solid black line indicates patients with 370 
STEMI, the dotted blue line patients with NSTE-ACS, and the dotted green line patients with SIHD.  371 
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Figure 4: 373 
Landmark analysis of definite stent thrombosis with the landmark set at 30 days. The solid black line 374 
indicates patients with STEMI, the dotted blue line patients with NSTE-ACS, and the dotted green line 375 
patients with SIHD. 376 
 377 
